UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2015

Q THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	000-52062	20-3708500
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

615 Arapeen Drive, Suite 102 Salt Lake City, UT		84108
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (801) 582-5400

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Resignation from Board of Directors

b) On December 11, 2015, Linda F. Powers resigned from the Board of Directors of the Company. Ms. Powers’ resignation did not result from any disagreement with the Company regarding its operations, policies or practices.

Compensatory Arrangements of Certain Officers

e) On December 11, 2015, the change-in-control provision contained in the employment agreements of Steven. J. Borst, Chief Executive Officer and David E. Green, Chief Financial Officer, were modified to extend the severance period in the event of a change in control for Mr. Borst to 36 months and for Mr. Green the severance period was extended to 24 months.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 17, 2015

Q THERAPEUTICS, INC.

/s/ STEVEN J. BORST

Steven J. Borst,

President and Chief Executive Officer

Q Therapeutics, Inc. 8-K